Light Therapy in Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

Light Therapy in Parkinson's Disease : Effect on Motor Symptoms, Sleep, Circadian Rhythms, and Mood

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02072642
• Other study ID #: 5063
• Status: Completed
• Phase: N/A
• Start date: April 2013
• Est. completion date: May 2023

Study information

• Verified date: August 2023
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease, a degenerative disorder of the dopaminergic system, combines motor symptoms but also non-motor, such as depression, sleep disorders and circadian rhythms and impaired cognitive functions. Difficulties in balancing the dopaminergic treatment of these patients emphasizes the need to find effective adjuvant therapies. Light therapy (LT) represents one such innovative therapeutic approach. Although light has an obvious to visual pathways within the brain, today it is known to additionally exert non-visual effects throughout the body. Recently our team has shown that non-visual, non-circadian light plays a major role in the regulation of sleep, as well as cognitive brain function in general. The retina, the primary conduit for the transmission of light information is weakened or thinned in Parkinson's patients. The dopamine system is known to enhance the processing of light information and intraocular injection of L-dopa in animal models of Parkinson's disease, can reverse associated motor symptoms. This allows for the possibility that LT would strengthen the dopaminergic tone in the central nervous system. However, to this date its effectiveness for alleviating Parkinson's symptoms has only been suggested by two studies, both poorly controlled. Thus, through the convergence of basic and clinical data, a study examining the effect of LT directly in people Parkinson's disease symptoms, whilst controlling for the effects on sleep, circadian system, mood, and cognitive functioning, is of extreme importance. With this information our hope is to determine if these polymorphisms allow for a predictive model of response to LT treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: May 2023
• Est. primary completion date: March 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Idiopathic Parkison's Disease, low or moderately severe
• Hoehn&Yahr <4
• 4 to < 15 years of evolution·
• Between 45-75 years old
• Absence of dementia : MMSE > 23·
• No severe depression
• Stable medication levels during the 5 weeks before inclusion

Exclusion Criteria:

• Secondary or severe Parkinson's disease
• Ocular pathologies (i.e. retinopathy)
• Photosensitive medication
• Antidepressant treatment·
• Major depression syndrome
• MMSE < 23
• Circadian rhythm problems
• Sleep apnea syndrome
• Manifested or acute psychiatric comorbidities
• Pregnant women

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• active light therapy : Light therapy: DayVia lamp 10000 lux
4 weeks of active light therapy with DayVia lamp 10000 lux
• Placebo light therapy
4 weeks with Placebo light therapy

Locations

Country	Name	City	State
France	University Hospital, Strasbourg, france	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global score :Unified Parkinson's Disease Rating Scale (UPDRS) I II III		5 weeks